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Fibrinogen mediates the processes of platelet aggre-
gation and clot retraction. Previous studies have dem-
onstrated that fibrinogen binding to the platelet recep-
tor aIIbb3 requires the C-terminal residues of the
fibrinogen g chain. We made a recombinant human fi-
brinogen that lacks the g chain C-terminal four residues
(AGDV). As expected this fibrinogen did not support
platelet aggregation. Unexpectedly, this variant did sup-
port clot retraction that was indistinguishable from re-
traction with normal recombinant or plasma fibrinogen.
These results suggest that the site on fibrinogen that is
required for platelet aggregation differs from the site on
fibrin that is required for clot retraction.
The processes of platelet aggregation and clot retraction are
mediated by fibrinogen in vitro and play a role in maintaining
hemostasis in vivo. Fibrinogen is a large (340 kDa) plasma
protein consisting of two sets of Aa, Bb, and g chains. The
protein is arranged in a symmetrical fashion with two lateral D
domains and a central E domain (1). Previous work employing
electron microscopy (2), synthetic peptides (3), and recombi-
nant proteins (4, 5) has implicated the D domain, in particular
residues g408–411 (AGDV), as the site on fibrinogen that
interacts with platelets. This interaction involves the platelet
integrin aIIbb3, a heterodimeric transmembrane receptor.
Antibodies and peptides that prevent fibrinogen binding to
aIIbb3 also prevent platelet aggregation and clot retraction
(6–8). Together, these findings predict that the aIIbb3 recogni-
tion site on fibrinogen (i.e. residues g408–411) must be present
and accessible for aggregation or clot retraction to occur. Two
studies support this prediction with respect to platelet aggre-
gation (4, 5), but both have limitations. In one (4), recombinant
g chains lacking residues 408–411 were unable to support
platelet aggregation; however, this variant g chain was studied
outside the context of the entire molecule. In the other (5),
recombinant fibrinogen with a 20-amino acid insert in place of
these four residues was unable to support platelet aggregation.
However, the lack of aggregation cannot be directly attributed
to the loss of the AGDV residues, as the additional 20 amino
acids may sterically impair aggregation. Moreover, neither
study explored the effects that these alterations may have had
on clot retraction.
We report that an intact recombinant fibrinogen lacking only
residues g408–411 does not support aggregation, consistent
with previous work (4, 5), but unexpectedly supports clot re-
traction to the same extent as normal recombinant and plasma
fibrinogen. These findings suggest that other domains in fibrin-
ogen participate in clot retraction.
MATERIALS AND METHODS
Construction of Expression Vectors—pMLP-Aa, pMLP-Bb, and
pMLP-g encoding the Aa, Bb, and g chains of human fibrinogen have
been described previously (9, 10). The vector pMLP-g407 was con-
structed from pMLP-g and p647, described in Hettasch et al. (4). The
C-terminal nucleotides from the Escherichia coli expression vector
p647(g407), which includes a stop codon at position 408, were removed
as a HindIII to BstXI fragment. The corresponding sites on pMLP-g
were cleaved with NotI and BstXI. The NotI and HindIII sites were
blunt ended with T4 polymerase. The fragment from p647 was ligated
into the cleaved vector to give pMLP-g407. The resulting mammalian
expression vector was sequenced using an Applied Biosystems auto-
mated sequencer (Foster City, CA). Restriction digests and general
cloning procedures have been described (9).
Cell Culture—CHO1 transfections and growth conditions have been
described (9). Normal recombinant fibrinogen, the predominant form
found in human plasma, was secreted from CHO cells containing the
pMLP-Aa, pMLP-Bb, and pMLP-g vectors. Cell line CHO-g407 was
constructed by transfecting pMLP-g407 into CHO cells harboring
pMLP-Aa and pMLP-Bb. Transfected cells were selected in medium
containing G418 (Life Technologies, Inc.), a neomycin analog, and his-
tidinol (Aldrich). Fibrinogen production was monitored by enzyme-
linked immunosorbent assay as described previously (9). Serum-free
medium was pooled and stored at 220 °C until the fibrinogen was
purified.
Purification of Recombinant Fibrinogen—Recombinant fibrinogen
was purified from CHO serum-free medium as described (10). Briefly,
fibrinogen was precipitated from the medium with 40% (NH4)2SO4, and
the precipitate was resuspended and purified by protamine-Sepharose
chromatography. Purification was monitored by electrophoresis on 8%
polyacrylamide gels by the method of Laemmli (11). Western blot anal-
ysis was performed as described (9) with a polyclonal antibody that
reacts with fibrinogen and its degradation products (DAKO Corpora-
tion, Carpinteria, CA) and 4A5, a monoclonal antibody specific for the C
terminus of the g chain (12). Monoclonal antibody 4A5 was the generous
gift of Dr. Gary Matsueda, Bristol-Myers Squibb Pharmaceuticals
(Princeton, NJ). Plasma fibrinogen was purchased from Calbiochem
(La Jolla, CA).
Isolation of Human Platelets—Human blood (60 ml) from healthy
volunteers who had abstained from aspirin for 10 days was collected
into polypropylene tubes containing 1:7 acid/citrate/dextrose anticoag-
ulant. Platelet-rich plasma was obtained by centrifugation at 200 3 g
for 25 min at ambient temperature. Prostaglandin E1 (Sigma) was
added to a final concentration of 20 nM. The platelet-rich plasma was
then centrifuged at 800 3 g for 25 min, and the platelet pellet was
resuspended in Tyrode’s buffer, pH 7.2 (10 mM Hepes, 135 mM NaCl, 2.7
mM KCl, 12 mM NaHCO3, 5.5 mM glucose, 2% bovine serum albumin
(fraction V, Miles Pentex)). The platelets were applied to a Sepharose
CL-2B column (Sigma) equilibrated with Tyrode’s buffer and were
eluted with the same buffer. The platelets were counted using a Coulter
counter (Hialeah, FL) and adjusted to a final concentration of 2 3 108
ml21 in Tyrode’s buffer with 1 mM Ca21 and 2 mM Mg21.
Platelet Aggregation Assay—Platelet aggregation in Tyrode’s buffer
was monitored with a platelet aggregometer (Chrono-Log). Fibrinogen
(final concentration, 250 nM) was added to 0.4-ml platelet suspensions
(2 3 108 platelets/ml) stirred at 37 °C. Aggregation was monitored by
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the percent change in light transmission following activation with 10
mM ADP (Sigma). Platelet aggregation in the absence of added fibrino-
gen or ADP was negligible.
Clot Retraction Assay—Clot retraction experiments were performed
following the procedure of Tuszynski et al. (7). Gel-filtered platelets (2
3 108 platelets/ml) were preincubated at 37 °C for 10 min with 300 nM
fibrinogen to give a final volume of 0.5 ml. Human a-thrombin, a
generous gift of Dr. Frank Church, University of North Carolina
(Chapel Hill, NC), was added to a final concentration of 0.5 unit/ml. The
clots formed without stirring in ,5 min and were incubated at 37 °C for
15 min. The tubes were transferred to ice and photographed 1 h later.
An alternative method of measuring retraction involved a modified
version of the Chen et al. procedure (8). Clot length and width were
measured with a ruler every 2 min following the addition of thrombin
and were used to calculate clot area. Control experiments were per-
formed in the absence of platelets or the absence of added fibrinogen.
Addition of thrombin to platelet suspensions without added fibrinogen
did not result in clot formation, and addition of thrombin to fibrinogen
solutions in the absence of platelets resulted in a fibrin clot that did not
retract.
RESULTS AND DISCUSSION
We characterized the purified recombinant proteins by SDS-
polyacrylamide gel electrophoresis and Western blots. SDS-
polyacrylamide gel electrophoresis run under reducing condi-
tions (Fig. 1) demonstrated that all three chains were present
in both the normal recombinant fibrinogen and the g407 vari-
ant. Electrophoresis under non-reducing conditions showed
that the chains assembled into a protein with a molecular mass
of 340 kDa (data not shown). Western blot analysis with a
polyclonal antibody (Fig. 2A) confirmed the presence of all
three chains in both recombinant proteins. A duplicate blot
developed with monoclonal antibody 4A5 (Fig. 2B), a mono-
clonal antibody specific for the C terminus of the g chain,
showed immunoreactivity with both plasma and normal recom-
binant fibrinogen but not with the g407 variant. Thus, the
C-terminal epitope for 4A5 has been perturbed in the g407
variant. This result is consistent with the lack of g chain
residues 408–411, as predicted from the DNA sequence data of
the g chain expression plasmid.
We tested the recombinant proteins in platelet aggregation
assays (Fig. 3). Platelets were activated upon addition of 10 mM
ADP, as indicated by the initial decrease in light transmission
due to platelet shape change (13). Following activation, platelet
samples in the presence of normal recombinant fibrinogen ex-
hibited a dramatic increase in light transmission due to the
formation of aggregates (14). In contrast, platelets in the pres-
ence of g407 changed shape but did not aggregate. Similar
results were obtained with the addition of ADP to platelets in
the absence of added fibrinogen (data not shown).
We examined clot retraction to see if the region on fibrinogen
required for aggregation was also required for this seemingly
related process. The clot formed in the presence of g407 was
indistinguishable from the clots formed with plasma or normal
recombinant fibrinogen. Clot retraction was followed for 20 min
at 37 °C. Retraction rates were similar for both normal recom-
binant and g407 fibrinogen (Fig. 4). The final contracted clots
formed with normal recombinant, g407, or plasma fibrinogen
FIG. 1. Polyacrylamide gel electrophoresis on 8% gels run un-
der reduced conditions according to themethod of Laemmli (11)
and developed with Coomassie Brilliant Blue R-250. Lanes: 1,
plasma fibrinogen; 2, normal recombinant fibrinogen; 3, recombinant
g407 fibrinogen.
FIG. 2.Western blot analysis of recombinant fibrinogen under
reduced conditions. An 8% polyacrylamide gel, run as in Fig. 1, was
blotted onto a nitrocellulose membrane and developed as in Binnie et al.
(9). Lanes: 1, plasma fibrinogen; 2, normal recombinant fibrinogen; 3,
recombinant g407 fibrinogen. Primary antibodies were: A, rabbit poly-
clonal antiserum reactive with all three fibrinogen chains; B, 4A5, a
monoclonal antibody specific for the C terminus of the g chain (10).
FIG. 3. ADP-induced aggregation of platelets. Platelets (2 3 108
platelets/ml) were preincubated at 37 °C with 250 nM fibrinogen prior to
activation with 10 mM ADP (indicated by arrows). Aggregation of stirred
solutions was measured as the increase in light transmission. Curve A
is for normal recombinant; curve B is for recombinant g407 fibrinogen.
FIG. 4. Time course for clot retraction. Platelets (2 3 108 plate-
lets/ml) were preincubated with 300 nM fibrinogen (to give a final
volume of 0.5 ml) at 37 °C for 10 min prior to the addition of 0.5 unit/ml
human a-thrombin. The clots were incubated at 37 °C, and length and
width were measured in mm at the indicated times. The figure presents
the average clot area (n 5 2).White bars represent normal recombinant
fibrinogen, and black bars represent g407 fibrinogen.
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(Fig. 5) were also indistinguishable. When thrombin was added
to platelet suspensions without added fibrinogen, there was no
clot formation (Fig. 5). When thrombin was added to solutions
of recombinant or plasma fibrinogen, fibrin clots formed but did
not retract (data not shown). Thus, the residues AGDV on the
g chain of fibrinogen are apparently not required for clot
retraction.
Because activation of platelets by thrombin results in the
release of fibrinogen from the a-granules (15), it is possible that
the platelet fibrinogen may contribute to the retraction of the
clots. Therefore, we plan to perform clot retraction experiments
using platelets from an afibrinogenemic patient, which will
serve as a definitive control.
In the experiments discussed here, we used genetic engineer-
ing to produce a variant fibrinogen molecule to probe two
seemingly related events. Consistent with previous results,
removal of the C-terminal AGDV residues from the g chain of
fibrinogen abolished the ability of the protein to support plate-
let aggregation. Unexpectedly, deletion of these residues did
not impair clot retraction. This finding apparently contradicts
previous findings that implicate AGDV in binding to aIIbb3
during clot retraction. We hypothesize that aIIbb3 interacts
with residues AGDV during aggregation and interacts with one
or both of the consensus binding sequences for integrins (RGD)
in the Aa chain during clot retraction. It has been shown that
the peptide RGDS can retard clot retraction (16). Using mono-
clonal antibodies, other investigators have shown that inacces-
sible sites on fibrinogen become accessible upon conversion to
fibrin (17). Perhaps the RGD sites are not accessible in fibrin-
ogen but are exposed in the fibrin molecule. These regions on
the Aa chain may then interact with aIIbb3 and mediate fibrin-
platelet interactions, including clot retraction. Thus, the ligand
site on fibrinogen that mediates aggregation may differ from
the site on fibrin that mediates clot retraction. Yet, the platelet
receptor for both processes is aIIbb3 (7, 8, 18). We plan to test
the hypothesized role of RGD in clot retraction by analysis of
additional variant fibrinogens.
In summary, we find that the g chain C-terminal residues
AGDV are critical for platelet aggregation but not for clot
retraction. These findings suggest a separate role for the con-
sensus binding sequence RGD at either position 95–97 or 572–
574 on the Aa chain of fibrinogen. Finally, the g407 variant
may also provide a means of differentiating between platelet
signaling events involved in aggregation versus clot retraction.
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FIG. 5. Photographs of the final retracted clots. Platelets (2 3
108 platelets/ml) were preincubated with 300 nM fibrinogen (to give a
final volume of 0.5 ml) at 37 °C for 10 min prior to the addition of 0.5
unit/ml human a-thrombin. The clots were incubated at 37 °C for 15
min and transferred to ice. The photograph was taken after 1 h. Tubes:
1, normal recombinant fibrinogen; 2, recombinant g407 fibrinogen; 3,
plasma fibrinogen; 4, no added fibrinogen.
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